{"entity":{"id":"paper-oncoseek-eclinicalmedicine-2023","kind":"paper","name":"A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study","aka":[],"tldr":"SeekIn's first OncoSeek study: an artificial intelligence model on seven routine protein tumour markers found about half of cancers while flagging about seven in a hundred people without cancer.","summary":"Luan and colleagues analysed 7,565 participants (954 with cancer) from SeekIn and Sun Yat-sen Memorial Hospital plus a Johns Hopkins validation cohort (1,005 with cancer, 812 without). Using one threshold per marker the seven markers had 56.9% specificity; the OncoSeek algorithm, combining the markers with age and sex, raised specificity to 92.9% (92.3 to 93.5) with overall sensitivity 51.7% (49.4 to 53.9). Sensitivities for nine common cancers ranged from 37.1% to 77.6% (pancreatic 77.6%), and tissue of origin was correct in 66.8% of true positives.","asOf":"2026-10-29","links":[{"label":"eClinicalMedicine 2023","url":"https://doi.org/10.1016/j.eclinm.2023.102041"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37387788/"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","proteomics"],"targets":[],"drugs":["oncoseek"],"companies":["seekin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"eClinicalMedicine","year":2023,"doi":"10.1016/j.eclinm.2023.102041","pmid":"37387788","authors":"Luan Y, Zhong G, Li S, et al.","paperType":"observational","findings":["Specificity 92.9%, sensitivity 51.7%.","Tissue of origin correct in 66.8% of true positives."],"whatItMeans":"Cheap and runs on hospital analysers, but at about 93% specificity a screening programme would generate many false alarms for each cancer found.","caveats":["Retrospective case-control analysis of routine testing data.","Authors include SeekIn staff."],"changedPractice":false,"participants":9382},"route":"/key-papers/paper-oncoseek-eclinicalmedicine-2023/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"drug":[{"id":"oncoseek","kind":"drug","name":"OncoSeek","route":"/drugs/oncoseek/"}],"company":[{"id":"seekin","kind":"company","name":"SeekIn","route":"/companies/seekin/"}]}}